Fulzerasib
 | |
| Clinical data | |
|---|---|
| Other names | Dupert; GFH-925; IBI-351 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C33H32ClFN6O4 |
| Molar mass | 631.11 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Fulzerasib is a drug that is approved in China to treat KRAS G12C-positive non-small cell lung cancer (NSCLC).[2][1][3]
Prior to marketing approval, fulzerasib had received two breakthrough therapy designations, the first for advanced G12C-mutant NSCLC and a second, for colorectal cancer (CRC) from the Center for Drug Evaluation (CDE) of the Chinese National Medical Products Administration (NMPA).[4]
References
[edit]- 1 2 Lamb YN (December 2024). "Fulzerasib: First Approval". Drugs. 84 (12): 1665–1671. doi:10.1007/s40265-024-02120-6. PMID 39587006.
- ↑ "Fulzerasib - GenFleet Therapeutics". AdisInsight. Springer Nature Switzerland AG.
- ↑ Jiang T, Lin C, Le S, Zhang L, Liang T, Cai L, et al. (August 2025). "Discovery of Fulzerasib (GFH925) for the Treatment of KRAS G12C-Mutated Solid Tumors". Journal of Medicinal Chemistry. 68 (15) acs.jmedchem.4c03183: 15386–15402. doi:10.1021/acs.jmedchem.4c03183. PMID 40701936.
- ↑ "Fulzerasib Phase II KROCUS Study | ASCO 2024". DelveInsight Business Research LLP. 2025.
 | This pharmacology-related article is a stub. You can help Wikipedia by adding missing information. |